How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentGHANIMA, Waleed; GODEAU, Bertrand; CINES, Douglas B et al.Blood. 2012, Vol 120, Num 5, pp 960-969, issn 0006-4971, 10 p.Article

A Review of Second- line Chemotherapy and Prognostic Models for Disseminated Germ Cell TumorsVOSS, Martin H; FELDMAN, Darren R; BOSL, George J et al.Hematology/oncology clinics of North America. 2011, Vol 25, Num 3, issn 0889-8588, viii-ix, 557-576 [22 p.]Article

Extracorporeal photochemotherapy as second- or first-line therapy of acute GVHD?MERTIN, E; PAILLARD, C; ROCHETTE, E et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 5, pp 963-965, issn 0268-3369, 3 p.Article

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group reportCREUTZIG, U; ZIMMERMANN, M; STARY, J et al.Leukemia. 2012, Vol 26, Num 4, pp 654-661, issn 0887-6924, 8 p.Article

Current Management of Pyogenic Liver Abscess: Surgery is Now Second-Line TreatmentMEZHIR, James J; FONG, Yuman; JACKS, Lindsay M et al.Journal of the American College of Surgeons. 2010, Vol 210, Num 6, pp 975-983, issn 1072-7515, 9 p.Article

Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South AfricaLEVISON, Julie H; ORRELL, Catherine; LOSINA, Elena et al.Antiviral therapy (London). 2011, Vol 16, Num 6, pp 853-861, issn 1359-6535, 9 p.Article

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?JABBOUR, Elias; KANTARJIAN, Hagop M; O'BRIEN, Susan et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4260-4265, issn 0732-183X, 6 p.Article

Second-line chemotherapy in patients with primary unknown cancerONO, Makiko; ANDO, Masashi; YONEMORI, Kan et al.Journal of cancer research and clinical oncology. 2011, Vol 137, Num 8, pp 1185-1191, issn 0171-5216, 7 p.Article

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line TherapyROSINA THALLINGER, Christiane Maria; RADERER, Markus; HEJNA, Michael et al.Journal of clinical oncology. 2011, Vol 29, Num 35, pp 4709-4714, issn 0732-183X, 6 p.Article

Hypertension artérielle : traitement de deuxième ligne : D'autres monothérapies = Arterial hypertension and second choice therapiesLa Revue Prescrire. 2008, Vol 28, Num 293, pp 196-198, issn 0247-7750, 3 p.Article

The Importance of Patient Participation in Second-Line Chemotherapy Decisions : Perspectives of African-American PatientsPHIPPS, Etienne; MADISON, Nora; POLANSKY, Marcia et al.Journal of the National Medical Association. 2008, Vol 100, Num 12, pp 1434-1440, issn 0027-9684, 7 p.Article

Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line TherapyRAUGI, Dana N; SMITH, Robert A; DIA BADIANE, Ndeye Mery et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 6, pp 2751-2760, issn 0066-4804, 10 p.Article

Traitement de deuxième ligne du cancer bronchique non à petites cellules = Second line treatment of non-small-cell lung cancerQUOI, E; WESTEEL, V; PEROL, M et al.La Lettre du cancérologue (Boulogne). 2010, Vol 19, Num 9, pp 547-555, issn 1165-113X, 9 p.Article

New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in TherapyARNOLD, Dirk; STEIN, Alexander.Drugs (Basel). 2013, Vol 73, Num 9, pp 885-893, issn 0012-6667, 9 p.Article

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line TherapiesMATSUZAKI, Juntaro; SUZUKI, Hidekazu; NISHIZAWA, Toshihiro et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1643-1645, issn 0066-4804, 3 p.Article

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemiaSU JIN LEE; CHUL WON JUNG; KIM, Dae-Young et al.American journal of hematology. 2011, Vol 86, Num 4, pp 346-350, issn 0361-8609, 5 p.Article

Short Time to Progression under First-Line Chemotherapy Is a Negative Prognostic Factor for Time to Progression and Residual Survival under Second-Line Chemotherapy in Advanced Pancreatic CancerHERRMANN, Christina; ABEL, Ulrich; STREMMEL, Wolfgang et al.Oncology. 2007, Vol 73, Num 5-6, pp 335-339, issn 0030-2414, 5 p.Article

Cost-Effectiveness of Second-Line Chemotherapy/ Biologics among Elderly Metastatic Colon Cancer PatientsZHIYUAN ZHENG; ONUKWUGHA, Eberechukwu; HANNA, Nader et al.Advances in therapy. 2014, Vol 31, Num 7, pp 724-734, issn 0741-238X, 11 p.Article

Second-line therapy for refractory renal-cell carcinomaZUSTOVICH, Fable; LOMBARDI, Giuseppe; NICOLETTO, Ornella et al.Critical reviews in oncology/hematology. 2012, Vol 83, Num 1, pp 112-122, issn 1040-8428, 11 p.Article

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular CarcinomaFINN, Richard S; KANG, Yoon-Koo; MULCAHY, Mary et al.Clinical cancer research (Print). 2012, Vol 18, Num 7, pp 2090-2098, issn 1078-0432, 9 p.Article

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)GILKS, Charles F; SARAH WALKER, A; SSALI, Francis et al.Antiviral therapy (London). 2012, Vol 17, Num 7, pp 1363-1373, issn 1359-6535, 11 p.Article

A Phase 2 Study of Tasisulam Sodium (LY573636 Sodium) as Second-Line Treatment for Patients With Unresectable or Metastatic MelanomaKIRKWOOD, John M; GONZALEZ, Rene; REINTGEN, Douglas et al.Cancer. 2011, Vol 117, Num 20, pp 4732-4739, issn 0008-543X, 8 p.Article

Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignanciesQI NIU; WEI WANG; YONG LI et al.International immunopharmacology (Print). 2011, Vol 11, Num 4, pp 449-456, issn 1567-5769, 8 p.Article

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-PDIZON, Don S; BLESSING, John A; MCMEEKIN, D. Scott et al.Journal of clinical oncology. 2009, Vol 27, Num 19, pp 3104-3108, issn 0732-183X, 5 p.Article

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaTARN, Constantine S; KANTARJIAN, Hagop; GARCIA-MANERO, Guillermo et al.Blood. 2008, Vol 112, Num 3, pp 516-518, issn 0006-4971, 3 p.Article